Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 279

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 2
Chunk 279
---
     -  
     5,020,117  
     (5,020,117) 
     (100.0)%
  
    Share-based inducement expense 
     (863,550) 
     -  
     (863,550) 
     (100.0)%
  
    Interest income (expense), net 
     14,626  
     (26,606) 
     41,232  
     155.0%
  
    Total other income (expense), net 
     (848,924) 
     4,951,959  
     (5,800,883) 
     (117.1)%

    Net loss 
     (10,523,246) 
     (4,748,348) 
     (5,774,898) 
     121.6%
  
    Deemed dividend on Series A, B and C Preferred Stock 
     (24,964,518) 
     -  
     (24,964,518) 
     100%
  
    Deemed dividend related to Series C Common Warrants 
     (84,083) 
     -  
     (84,083) 
     100%
  
    Net loss attributable to common stockholders 
    $(35,571,847) 
    $(4,748,348) 
    $(30,823,499) 
     649.1%

Research
and Development Expenses

Research and
development expenses were $5,662,000 for the six months ended June 30, 2025 as compared to $4,383,000 for the six months ended June
30, 2024, reflecting an increase of $1,279,000. The increase was primarily attributable to an increase in clinical expenses of
$2,362,000, and an increase in scientific consulting fees of $496,000. In the first quarter of 2025, we began clinical trials
related to the IND for CER-1236. This increase was primarily offset by a decrease in lab expenses of $461,000 primarily attributable
to a decrease in toxicology studies performed in the 2025 period as compared to the 2024 period, a decrease in research and development salaries and benefits of
approximately $989,000 which included a decrease in stock-based compensation expense of $723,000 primarily attributable